CA3013845C - METHODS FOR THE TREATMENT OF THE PIK3CA-RELATED OVERGROWTH SPECTRUM - Google Patents

METHODS FOR THE TREATMENT OF THE PIK3CA-RELATED OVERGROWTH SPECTRUM

Info

Publication number
CA3013845C
CA3013845C CA3013845A CA3013845A CA3013845C CA 3013845 C CA3013845 C CA 3013845C CA 3013845 A CA3013845 A CA 3013845A CA 3013845 A CA3013845 A CA 3013845A CA 3013845 C CA3013845 C CA 3013845C
Authority
CA
Canada
Prior art keywords
pros
byl719
pik3ca
overgrowth
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3013845A
Other languages
English (en)
French (fr)
Other versions
CA3013845A1 (en
Inventor
Guillaume Canaud
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Cite filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA3013845A1 publication Critical patent/CA3013845A1/en
Application granted granted Critical
Publication of CA3013845C publication Critical patent/CA3013845C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Spectrometry And Color Measurement (AREA)
CA3013845A 2016-02-19 2017-02-17 METHODS FOR THE TREATMENT OF THE PIK3CA-RELATED OVERGROWTH SPECTRUM Active CA3013845C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305193.1 2016-02-19
EP16305193 2016-02-19
PCT/EP2017/053587 WO2017140828A1 (en) 2016-02-19 2017-02-17 Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)

Publications (2)

Publication Number Publication Date
CA3013845A1 CA3013845A1 (en) 2017-08-24
CA3013845C true CA3013845C (en) 2024-09-17

Family

ID=55409795

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3013845A Active CA3013845C (en) 2016-02-19 2017-02-17 METHODS FOR THE TREATMENT OF THE PIK3CA-RELATED OVERGROWTH SPECTRUM

Country Status (8)

Country Link
US (4) US11433059B2 (https=)
EP (1) EP3416642A1 (https=)
JP (3) JP7051693B2 (https=)
KR (1) KR20180115297A (https=)
CN (3) CN118477076A (https=)
AU (3) AU2017219834B2 (https=)
CA (1) CA3013845C (https=)
WO (1) WO2017140828A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016265844B2 (en) 2015-05-15 2021-02-11 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
EP3416642A1 (en) 2016-02-19 2018-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)
KR20210124310A (ko) 2019-02-06 2021-10-14 벤테라, 인코포레이티드 국소 포스포이노시티드 3-키나제 억제제
JP2024516006A (ja) * 2021-05-03 2024-04-11 ノバルティス アーゲー アルペリシブ製剤
WO2025045915A1 (en) * 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy
WO2025045129A1 (zh) * 2023-08-30 2025-03-06 广州嘉越医药科技有限公司 化合物用于治疗pros谱系疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583357B (zh) * 2006-08-29 2013-03-20 新加坡国立癌症中心 Mtor拮抗剂和血管生成抑制剂用于制备治疗癌症的药物的用途
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
UA118846C2 (uk) * 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
AU2016265844B2 (en) * 2015-05-15 2021-02-11 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
EP3416642A1 (en) 2016-02-19 2018-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)

Also Published As

Publication number Publication date
AU2017219834B2 (en) 2022-06-30
US11433059B2 (en) 2022-09-06
JP2022058800A (ja) 2022-04-12
JP7847994B2 (ja) 2026-04-20
EP3416642A1 (en) 2018-12-26
KR20180115297A (ko) 2018-10-22
CN118477076A (zh) 2024-08-13
JP2019505549A (ja) 2019-02-28
US20250339417A1 (en) 2025-11-06
AU2022235569A1 (en) 2022-10-13
CN109562103A (zh) 2019-04-02
US12427141B2 (en) 2025-09-30
US20250295645A1 (en) 2025-09-25
AU2022235569B2 (en) 2024-10-10
JP2024125429A (ja) 2024-09-18
JP7051693B2 (ja) 2022-04-11
AU2017219834A1 (en) 2018-08-23
CN118477075A (zh) 2024-08-13
WO2017140828A1 (en) 2017-08-24
US20200215044A1 (en) 2020-07-09
CA3013845A1 (en) 2017-08-24
AU2024278598A1 (en) 2025-01-16
US20220323428A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
AU2022235569B2 (en) BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)
Luo et al. Perfect match: mTOR inhibitors and tuberous sclerosis complex
Venot et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome
EP3498278B1 (en) Compounds for treatment of diseases related to dux4 expression
Zhang et al. Mechanical stress regulates autophagic flux to affect apoptosis after spinal cord injury
RU2587053C2 (ru) Комбинированная терапия и способ оценки невосприимчивости к лечению
Hayes et al. Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin‐Deficient D2. B10‐Dmdmdx/J Mouse
Quinn et al. Effects of dantrolene therapy on disease phenotype in dystrophin deficient mdx mice
EP2919769A1 (en) Modulators of intracellular chloride concentration for treating fragile x syndrome
Botelho et al. Adrenal insufficiency by adrenoleukodystrophy
CN117396197A (zh) 慢性肾脏病的猫的治疗方法
EP3856340A1 (en) Combined sirolimus and nintedanib therapy for vascular lesions and hereditary hemorrhagic telangiectasia
US20260115220A1 (en) Treatment and/or prevention of skeletal muscle atrophy by inhibition of eda2r-nik and osm-osmr signaling pathways
TW202519221A (zh) Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合
Bonnard et al. Macrophage Neutrophil Gelatinase-Associated Lipocalin Has a Critical Role in Aldosterone-Induced Renal Fibrosis via the CCL5-IL4 Pathway: PO2129
Ardissino et al. Water Intake and Blood Pressure in Children: Results from the SPA Project: PO2130
Cheofor et al. Altered Tryptophan Catabolism via the Kynurenine Pathway Associates with CKD-Accelerated Atherosclerosis: PO2131
TW202606680A (zh) 角化症用醫藥組成物及其用途
WO2026021478A1 (zh) Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法
KR20260044564A (ko) 포비돈-프러시안 블루 나노자임을 유효성분으로 포함하는 골관절염의 예방, 치료 또는 개선용 조성물
WO2024128311A1 (ja) 脈管奇形用医薬組成物及び脈管奇形の治療方法
Brackhan Investigation of brain inflammation as a nuclear imaging biomarker of epileptogenesis and a treatment target for epilepsy prevention
Chen et al. 1Department of Critical Care Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, No. 136, Jingzhou Street, Xiangcheng District, Xiangyang 441021, Hubei, China. 2Department of Emergency Medicine, Xiangyang Central Hospital

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220119

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20240912

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20240917

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250115

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250115

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250115

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260120